Oral Presentation at the 24th Annual Meeting of J-mit 2025

Triplex Therapeutics Inc. is pleased to announce that CEO Takamitsu Yano will deliver an oral presentation at the 24th Annual Meeting of the Japanese Society of Mitochondrial Research and Medicine, held on November 14–15, 2025.

■ Presentation Information
Title:
“Clinical Risks and Unproven Efficacy of PI Polyamides Targeting Mutant Mitochondrial DNA (A3243G) in MELAS and Cancer Models”
Presenter: Takamitsu Yano (Triplex Therapeutics Inc.)
Session: Oral Session 3 (O-13)
Date & Time: November 15 (Sat), 9:00–9:50
(Listed in the official program, Day 2, O-13)

■ Overview
This presentation critically examines the clinical risks and lack of validated efficacy of PI polyamides binding and targeting to the A3243G mtDNA mutation（our ML1 polyamide is binding with normal mtDNA: employing a different strategy).

Key topics include:

・Toxicity concerns and nonspecific DNA interactions
・Insufficient evidence for MELAS therapy
・Re-evaluation of reported mechanisms in cancer models
・Regulatory and clinical risks of premature application
・Comparison with international standards in mitochondrial therapeutics

Triplex Therapeutics Inc. remains committed to promoting scientific integrity and patient safety in mitochondrial medicine.

■ Message
We look forward to engaging in thoughtful discussions with clinicians, researchers, and stakeholders.